Figure 4From: Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis Survival gain distribution in control group (a) and bevacizumab plus irinotecan group (b). The combination of bevacizumab and irinotecan showed benefit in survival time for patients with recurrent HGG.Back to article page